logo-loader

OptiBiotix to showcase industry-leading technology at top conference next month

Published: 19:21 17 Jan 2018 AEDT

gut schematic
The gut is host to a whole ecosystem of bacteria which helps promote good health

OptiBiotix Health plc’s (LON:OPTI) work on the emerging field of the human microbiome will be recognised at a leading industry conference next month.

For the company is to present an abstract at ProBiota 2018, attended by the movers and shakers of the industry.

READ: Optibiotix Health eyes up future projects

The poster and verbal exposition will focus on OptiBiotix's ability to identify and develop targeted prebiotics which can enhance the growth rate and health benefits of specific microbial species. In doing so they aid the efficacy of probiotic products.

Deeper dive

To understand what this means it is worth going back to first principles. As mentioned, the company’s focus is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

What it is showcasing at the ProBiota conference is a prebiotic which helps promote the growth of the health-giving micro-organisms such as Lactobacillus rhamnosus GG, or LGG for short.

This new product concept utilises OptiBiotix's synbiotics technology and has the potential to enhance probiotic health benefits and provide a product that is different to the current me-too offerings.

Designer prebiotics

“The ability to create designer prebiotics which can selectively modulate the growth of an individual species and be used in combination to improve the efficacy of existing probiotics, or by itself to modify an individual's microbiome to improve health, is a hugely exciting development in global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“We believe we are fast approaching a future where microbiome products will make a significant contribution to the prevention, management and treatment of disease.

“The ability to create designer ingredients which can precision engineer the microbiome to improve health places OptiBiotix at the forefront of this global health trend."

ProBiota 2018 takes place in Barcelona February 7-9.

OzAurum to start drilling at Boca Rica Lithium Project

OzAurum Resources Ltd (ASX:OZM) CEO and managing director Andrew Pumphrey sits down with Proactive’s Jonathan Jackson to discuss an upcoming drilling program at Boca Rica Lithium Project in Brazil, following the identification of a spodumene zone. The company plans to start drilling in the next...

4 hours, 14 minutes ago